Craig-Hallum Reaffirms Buy on GeneDx (WGS) With $153 Price Target

On March 12, 2026, Craig-Hallum reaffirmed its Buy standing connected GeneDx Holdings Corp. (NASDAQ:WGS) and maintained a terms people of $153 connected the company’s banal pursuing information presented astatine the ACMG Annual Meeting. The information indicated that the company’s full exome and genome investigating notably reduces healthcare assets utilization and full healthcare costs. Analysts judge these findings fortify GeneDx Holdings Corp. (NASDAQ:WGS)’s capabilities successful the commercialized and Medicaid sum expansion. The steadfast remains bullish contempt the company’s shares witnessing a 9% diminution connected the aforesaid day, aft its rival Natera launched its Zenith genomics assay, which aims astatine offering improved detection of uncommon diseases.

Separately, connected February 24, 2026, BTIG expert Mark Massaro maintained the firm’s Buy standing connected GeneDx Holdings Corp. (NASDAQ:WGS) but adjusted the terms people from $200 to $170. The steadfast remains bullish pursuing a beardown Q4 bushed and besides expressed assurance successful the company’s fundamentals and caller opportunities.

Founded successful 2000, GeneDx Holdings Corp. (NASDAQ:WGS) is simply a person successful uncommon illness genomics and exome/genome sequencing, with office successful Maryland.

While we admit the imaginable of WGS arsenic an investment, we judge definite AI stocks connection greater upside imaginable and transportation little downside risk. If you're looking for an highly undervalued AI banal that besides stands to payment importantly from Trump-era tariffs and the onshoring trend, spot our escaped study connected the best short-term AI stock.

READ NEXT: 10 Best Stocks to Invest successful During a Recession and 10 Best Space Exploration Stocks to Buy According to Analysts

Disclosure: None. Follow Insider Monkey connected Google News.